Researchers at the Massachusetts General Hospital Cancer Center have discovered that a combination of two drugs delays treatment resistance in patients afflicted with advanced melanoma. Dabrafenib and trametinib, kinase inhibitor drugs, "postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma." Considered to be the most serious form of skin cancer, the researchers state that drugs which inhibit BRAF activity can stop, even reverse tumor growth in 90% of melanoma patients. Unfortunately however, this response is temporary in the majority of cases, with tumor growth resuming after 6 or 7 months.
To read more about this study, click here.
No comments:
Post a Comment